Last reviewed · How we verify
NCT02988388: LTRC
Lung Tissue Research Consortium
trial testing Lung biopsy/lobectomy in Chronic Obstructive Pulmonary Disease in 247 participants. Completed in 21 February 2019.
28 January 2019
Quick facts
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 247 |
| Start date | 23 February 2017 |
| Primary completion | 28 January 2019 |
| Estimated completion | 21 February 2019 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Lung biopsy/lobectomy
Conditions studied
- Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
- Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Who can join
21 and older, any sex, with Chronic Obstructive Pulmonary Disease or Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The LTRC will facilitate histopathological research of pulmonary diseases by collecting lung tissues from donors and preparing and distributing collections of tissue specimens to researchers within and outside the LTRC. Collections of specimens will be linked to individual clinical data appropriate to the particular disease. The primary goal of the LTRC is to identify participants with suspected lung cancer or metastatic disease who are willing to provide informed consent for research use of their specimens and data. Secondarily, the LTRC investigators intend to collect clinical data, limited exposure data, physiologic studies, and radiographic studies from these participants.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis.
Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, et al · · 2022 · cited 108× · PMID 35688625 · DOI 10.1136/thoraxjnl-2021-218577 -
Integrative genetic and genomic networks identify microRNA associated with COPD and ILD.
Pavel AB, Garrison C, Luo L, Liu G, et al · · 2023 · cited 5× · PMID 37567908 · DOI 10.1038/s41598-023-39751-w -
Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associations.
Ryu MH, Yun JH, Kim K, Gentili M, et al · · 2024 · cited 4× · PMID 39695952 · DOI 10.1186/s12864-024-11031-5 -
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets
Chin D, Hernandez-Beeftink T, Donoghue L, Guillen-Guio B, et al · · 2025 · DOI 10.1101/2025.01.30.25321017 -
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosis
Leavy OC, Goemans AF, Stockwell AD, Allen RJ, et al · · 2024 · DOI 10.1101/2024.01.12.24301204
Verify or expand the search:
- PubMed search for NCT02988388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Obstructive Pulmonary Disease
Currently open trials in the same condition.
- NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
- NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
- NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
- NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting
Other National Heart, Lung, and Blood Institute (NHLBI) trials
Trials by the same sponsor.
- NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
- NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
- NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
- NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02988388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
- Last refreshed: 8 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02988388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing